George G. Zhanel - Publications

Affiliations: 
Medical Microbiology University of Manitoba, Winnipeg, Manitoba, Canada 
Area:
Microbiology Biology, Epidemiology

282 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Alexander D, Bay DC, Boyd D, McCracken M, Mulvey MR, Zhanel GG. Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing Escherichia coli clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007-2017). Diagnostic Microbiology and Infectious Disease. 114962. PMID 31859022 DOI: 10.1016/j.diagmicrobio.2019.114962  0.48
2019 Lagacé-Wiens PRS, Adam HJ, Poutanen S, Baxter MR, Denisuik AJ, Golden AR, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Golding G, Hoban DJ, Zhanel GG. Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16. The Journal of Antimicrobial Chemotherapy. 74: iv22-iv31. PMID 31505648 DOI: 10.1093/jac/dkz284  0.48
2019 Denisuik AJ, Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Mulvey MR, Hoban DJ, Zhanel GG. Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016. The Journal of Antimicrobial Chemotherapy. 74: iv64-iv71. PMID 31505647 DOI: 10.1093/jac/dkz289  0.48
2019 Nichol KA, Adam HJ, Golding GR, Lagacé-Wiens PRS, Karlowsky JA, Hoban DJ, Zhanel GG. Characterization of MRSA in Canada from 2007 to 2016. The Journal of Antimicrobial Chemotherapy. 74: iv55-iv63. PMID 31505646 DOI: 10.1093/jac/dkz288  0.48
2019 Golden AR, Baxter MR, Davidson RJ, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG, Adam HJ. Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16. The Journal of Antimicrobial Chemotherapy. 74: iv39-iv47. PMID 31505644 DOI: 10.1093/jac/dkz286  0.48
2019 McCracken MG, Adam HJ, Blondeau JM, Walkty AJ, Karlowsky JA, Hoban DJ, Zhanel GG, Mulvey MR. Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study. The Journal of Antimicrobial Chemotherapy. 74: iv32-iv38. PMID 31505643 DOI: 10.1093/jac/dkz285  0.48
2019 Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Golden AR, Hink R, Lagacé-Wiens PRS, Walkty A, Mulvey MR, Schweizer F, Bay D, Hoban DJ, Karlowsky JA, et al. 42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study. The Journal of Antimicrobial Chemotherapy. 74: iv5-iv21. PMID 31505641 DOI: 10.1093/jac/dkz283  0.48
2018 Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Boyd D, Bharat A, Mulvey MR, Charles M, Bergevin M, Zhanel GG. Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017). Diagnostic Microbiology and Infectious Disease. PMID 30638654 DOI: 10.1016/j.diagmicrobio.2018.12.005  0.48
2018 Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M, Nichol KA, Lagacé-Wiens P, Walkty AJ, Karlowsky JA, Hoban DJ, Mulvey MR, Zhanel GG. Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. The Journal of Antimicrobial Chemotherapy. PMID 30500898 DOI: 10.1093/jac/dky477  0.48
2018 Golden AR, Adam HJ, Karlowsky JA, Baxter M, Nichol KA, Martin I, Demczuk W, Van Caeseele P, Gubbay JB, Lefebvre B, Levett PN, Zahariadis G, Haldane D, Gad R, German G, ... ... Zhanel GG, et al. Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15. The Journal of Antimicrobial Chemotherapy. 73: vii20-vii31. PMID 29982573 DOI: 10.1093/jac/dky157  0.48
2018 Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG. Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15. The Journal of Antimicrobial Chemotherapy. 73: vii12-vii19. PMID 29982572 DOI: 10.1093/jac/dky158  0.48
2018 Karlowsky JA, Adam HJ, Golden AR, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG. Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15. The Journal of Antimicrobial Chemotherapy. 73: vii5-vii11. PMID 29982570 DOI: 10.1093/jac/dky156  0.48
2018 Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. PMID 29748749 DOI: 10.1007/s40265-018-0910-x  0.48
2017 Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16. The Journal of Antimicrobial Chemotherapy. PMID 29244121 DOI: 10.1093/jac/dkx468  0.48
2017 Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. PMID 29230684 DOI: 10.1007/s40265-017-0851-9  0.48
2017 Lagacé-Wiens PRS, Adam HJ, Laing NM, Baxter MR, Martin I, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG. Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential. The Journal of Antimicrobial Chemotherapy. PMID 28505331 DOI: 10.1093/jac/dkx147  0.48
2016 Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs. PMID 27909995 DOI: 10.1007/s40265-016-0667-z  0.48
2016 Gorityala BK, Guchhait G, Goswami S, Fernando DM, Kumar A, Zhanel GG, Schweizer FM. Hybrid antibiotic overcomes resistance in P. aeruginosa by enhancing outer membrane penetration and reducing efflux. Journal of Medicinal Chemistry. PMID 27524179 DOI: 10.1021/acs.jmedchem.6b00867  0.48
2016 Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale. 2016: 2082693. PMID 27366158 DOI: 10.1155/2016/2082693  0.48
2016 Zhanel GG, Del Rosso JQ. Activity of Dapsone versus Community and Hospital Pathogens from the CANWARD Study. The Journal of Clinical and Aesthetic Dermatology. 9: 42-7. PMID 27354888  0.48
2016 Golden AR, Adam HJ, Zhanel GG. Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. PMID 27085174 DOI: 10.1016/j.vaccine.2016.03.058  0.48
2016 Zhanel GG, Karlowsky JA. Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity. Mbio. 7. PMID 26956585 DOI: 10.1128/mBio.00169-16  0.48
2016 Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs. 76: 567-88. PMID 26863149 DOI: 10.1007/s40265-016-0545-8  0.48
2016 Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PRS, Walkty A, Gin AS, Hoban DJ, Karlowsky JA. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent Drugs. 1-22. DOI: 10.1007/s40265-016-0545-8  0.48
2016 Domalaon R, Zhanel GG, Schweizer F. Short antimicrobial peptides and peptide scaffolds as promising antibacterial agents Current Topics in Medicinal Chemistry. 16: 1217-1230.  0.48
2015 Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale / Ammi Canada. 26: 305-12. PMID 26744587  0.48
2015 Gorityala BK, Guchhait G, Fernando DM, Deo S, McKenna SA, Zhanel GG, Kumar A, Schweizer F. Adjuvants Based on Hybrid Antibiotics Overcome Resistance in Pseudomonas aeruginosa and Enhance Fluoroquinolone Efficacy. Angewandte Chemie (International Ed. in English). PMID 26610184 DOI: 10.1002/anie.201508330  0.48
2015 Bharat A, Martin I, Zhanel GG, Mulvey MR. In vitro potency and combination testing of antimicrobial agents against Neisseria gonorrhoeae. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. PMID 26603424 DOI: 10.1016/j.jiac.2015.10.002  0.48
2015 Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 61: S58-68. PMID 26316559 DOI: 10.1093/cid/civ534  0.48
2015 Zhanel GG, Wolter KD, Karlowsky JA. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data-authors' response. The Journal of Antimicrobial Chemotherapy. 70: 3170-1. PMID 26242414 DOI: 10.1093/jac/dkv234  0.48
2015 Mehrad B, Clark NM, Zhanel GG, Lynch JP. Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest. 147: 1413-21. PMID 25940252 DOI: 10.1378/chest.14-2171  0.48
2015 Golden AR, Rosenthal M, Fultz B, Nichol KA, Adam HJ, Gilmour MW, Baxter MR, Hoban DJ, Karlowsky JA, Zhanel GG. Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13. The Journal of Antimicrobial Chemotherapy. 70: 2199-202. PMID 25921512 DOI: 10.1093/jac/dkv107  0.48
2015 Cordeiro RP, Doria JH, Zhanel GG, Sparling R, Holley RA. Role of glycoside hydrolase genes in sinigrin degradation by E. coli O157:H7. International Journal of Food Microbiology. 205: 105-11. PMID 25897994 DOI: 10.1016/j.ijfoodmicro.2015.04.008  0.48
2015 Simner PJ, Adam H, Baxter M, McCracken M, Golding G, Karlowsky JA, Nichol K, Lagacé-Wiens P, Gilmour MW, Hoban DJ, Zhanel GG. Epidemiology of Vancomycin-Resistant Enterococci in Canadian Hospitals (CANWARD Study, 2007 to 2013). Antimicrobial Agents and Chemotherapy. 59: 4315-7. PMID 25896693 DOI: 10.1128/AAC.00384-15  0.48
2015 Guchhait G, Altieri A, Gorityala B, Yang X, Findlay B, Zhanel GG, Mookherjee N, Schweizer F. Amphiphilic tobramycins with immunomodulatory properties. Angewandte Chemie (International Ed. in English). 54: 6278-82. PMID 25847672 DOI: 10.1002/anie.201500598  0.48
2015 Manges AR, Harel J, Masson L, Edens TJ, Portt A, Reid-Smith RJ, Zhanel GG, Kropinski AM, Boerlin P. Multilocus sequence typing and virulence gene profiles associated with Escherichia coli from human and animal sources. Foodborne Pathogens and Disease. 12: 302-10. PMID 25774654 DOI: 10.1089/fpd.2014.1860  0.48
2015 Golden AR, Adam HJ, Gilmour MW, Baxter MR, Martin I, Nichol KA, Demczuk WH, Hoban DJ, Zhanel GG. Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13. The Journal of Antimicrobial Chemotherapy. 70: 1960-4. PMID 25761605 DOI: 10.1093/jac/dkv061  0.48
2015 Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP, Karlowsky JA. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 75: 253-70. PMID 25673021 DOI: 10.1007/s40265-015-0352-7  0.48
2015 Jahan M, Zhanel GG, Sparling R, Holley RA. Horizontal transfer of antibiotic resistance from Enterococcus faecium of fermented meat origin to clinical isolates of E. faecium and Enterococcus faecalis. International Journal of Food Microbiology. 199: 78-85. PMID 25647243 DOI: 10.1016/j.ijfoodmicro.2015.01.013  0.48
2014 Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Zhanel GG. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013. Diagnostic Microbiology and Infectious Disease. 80: 311-5. PMID 25294303 DOI: 10.1016/j.diagmicrobio.2014.09.003  0.48
2014 Fernando DM, Xu W, Loewen PC, Zhanel GG, Kumar A. Triclosan can select for an AdeIJK-overexpressing mutant of Acinetobacter baumannii ATCC 17978 that displays reduced susceptibility to multiple antibiotics. Antimicrobial Agents and Chemotherapy. 58: 6424-31. PMID 25136007 DOI: 10.1128/AAC.03074-14  0.48
2014 So W, Crandon JL, Zhanel GG, Nicolau DP. Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter. Antimicrobial Agents and Chemotherapy. 58: 6931-3. PMID 25136006 DOI: 10.1128/AAC.03652-14  0.48
2014 Domalaon R, Yang X, O'Neil J, Zhanel GG, Mookherjee N, Schweizer F. Structure-activity relationships in ultrashort cationic lipopeptides: the effects of amino acid ring constraint on antibacterial activity. Amino Acids. 46: 2517-30. PMID 25069750 DOI: 10.1007/s00726-014-1806-z  0.48
2014 Zhanel GG, Wolter KD, Calciu C, Hogan P, Low DE, Weiss K, Karlowsky JA. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data. The Journal of Antimicrobial Chemotherapy. 69: 2835-40. PMID 24920652 DOI: 10.1093/jac/dku207  0.48
2014 Zhanel GG, Denisuik A, Vashisht S, Yachison C, Adam HJ, Hoban DJ. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model. The Journal of Antimicrobial Chemotherapy. 69: 2448-52. PMID 24827891 DOI: 10.1093/jac/dku149  0.48
2014 Walkty A, Adam H, Baxter M, Denisuik A, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrobial Agents and Chemotherapy. 58: 2554-63. PMID 24550325 DOI: 10.1128/AAC.02744-13  0.48
2014 Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 74: 31-51. PMID 24352909 DOI: 10.1007/s40265-013-0168-2  0.48
2014 Fani F, Leprohon P, Zhanel GG, Bergeron MG, Ouellette M. Genomic analyses of DNA transformation and penicillin resistance in Streptococcus pneumoniae clinical isolates. Antimicrobial Agents and Chemotherapy. 58: 1397-403. PMID 24342643 DOI: 10.1128/AAC.01311-13  0.48
2014 Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clinical and Experimental Pharmacology & Physiology. 41: 437-43. PMID 24341387 DOI: 10.1111/1440-1681.12195  0.48
2014 Karlowsky JA, Denisuik AJ, Lagacé-Wiens PR, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG. In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study. Antimicrobial Agents and Chemotherapy. 58: 1252-6. PMID 24323476 DOI: 10.1128/AAC.02399-13  0.48
2014 Wierzbowski AK, Karlowsky JA, Adam HJ, Nichol KA, Hoban DJ, Zhanel GG. Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008. The Journal of Antimicrobial Chemotherapy. 69: 59-66. PMID 23970485 DOI: 10.1093/jac/dkt332  0.48
2013 Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Canadian Journal of Microbiology. 59: 778-88. PMID 24313450 DOI: 10.1139/cjm-2013-0614  0.48
2013 Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrobial Agents and Chemotherapy. 57: 5600-11. PMID 23979759 DOI: 10.1128/AAC.01485-13  0.48
2013 Walkty A, Karlowsky JA, Adam H, Baxter M, Lagacé-Wiens P, Hoban DJ, Zhanel GG. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrobial Agents and Chemotherapy. 57: 5707-9. PMID 23939895 DOI: 10.1128/AAC.01404-13  0.48
2013 Lupien A, Billal DS, Fani F, Soualhine H, Zhanel GG, Leprohon P, Ouellette M. Genomic characterization of ciprofloxacin resistance in a laboratory-derived mutant and a clinical isolate of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 57: 4911-9. PMID 23877698 DOI: 10.1128/AAC.00418-13  0.48
2013 Hoban DJ, Zhanel GG. Introduction to the CANWARD study (2007–11). The Journal of Antimicrobial Chemotherapy. 68: i3-5. PMID 23720829 DOI: 10.1093/jac/dkt021  0.48
2013 Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. The Journal of Antimicrobial Chemotherapy. 68: i7-22. PMID 23587781 DOI: 10.1093/jac/dkt022  0.48
2013 Zelenitsky SA, Rubinstein E, Ariano RE, Zhanel GG. Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD). The Journal of Antimicrobial Chemotherapy. 68: i67-72. PMID 23587780 DOI: 10.1093/jac/dkt028  0.48
2013 Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. The Journal of Antimicrobial Chemotherapy. 68: i57-65. PMID 23587779 DOI: 10.1093/jac/dkt027  0.48
2013 Nichol KA, Adam HJ, Roscoe DL, Golding GR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. The Journal of Antimicrobial Chemotherapy. 68: i47-55. PMID 23587778 DOI: 10.1093/jac/dkt026  0.48
2013 Karlowsky JA, Adam HJ, Desjardins M, Lagacé-Wiens PR, Hoban DJ, Zhanel GG. Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals. The Journal of Antimicrobial Chemotherapy. 68: i39-46. PMID 23587777 DOI: 10.1093/jac/dkt025  0.48
2013 Adam HJ, Baxter MR, Davidson RJ, Rubinstein E, Fanella S, Karlowsky JA, Lagacé-Wiens PR, Hoban DJ, Zhanel GG. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. The Journal of Antimicrobial Chemotherapy. 68: i31-7. PMID 23587776 DOI: 10.1093/jac/dkt024  0.48
2013 Lagacé-Wiens PR, Adam HJ, Low DE, Blondeau JM, Baxter MR, Denisuik AJ, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Hoban DJ, Zhanel GG. Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. The Journal of Antimicrobial Chemotherapy. 68: i23-9. PMID 23587775 DOI: 10.1093/jac/dkt023  0.48
2013 Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 73: 159-77. PMID 23371303 DOI: 10.1007/s40265-013-0013-7  0.48
2013 Lynch JP, Clark NM, Zhanel GG. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases). Expert Opinion On Pharmacotherapy. 14: 199-210. PMID 23321047 DOI: 10.1517/14656566.2013.763030  0.48
2013 Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddell K, Rogers P, Qin X, Butler-Wu S, Price LB, Aziz M, Nicolas-Chanoine MH, Debroy C, Robicsek A, ... ... Zhanel G, et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. The Journal of Infectious Diseases. 207: 919-28. PMID 23288927 DOI: 10.1093/infdis/jis933  0.48
2012 Baudry-Simner PJ, Singh A, Karlowsky JA, Hoban DJ, Zhanel GG. Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale / Ammi Canada. 23: e60-4. PMID 23997786  0.48
2012 Bera S, Dhondikubeer R, Findlay B, Zhanel GG, Schweizer F. Synthesis and antibacterial activities of amphiphilic neomycin B-based bilipid conjugates and fluorinated neomycin B-based lipids. Molecules (Basel, Switzerland). 17: 9129-41. PMID 22858839 DOI: 10.3390/molecules17089129  0.48
2012 Findlay B, Szelemej P, Zhanel GG, Schweizer F. Guanidylation and tail effects in cationic antimicrobial lipopeptoids. Plos One. 7: e41141. PMID 22844435 DOI: 10.1371/journal.pone.0041141  0.48
2012 Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Shane A, Zhanel GG, Tyrrell GJ, Gilmour MW. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010. Canadian Journal of Microbiology. 58: 1008-17. PMID 22827750 DOI: 10.1139/w2012-073  0.48
2012 Dhondikubeer R, Bera S, Zhanel GG, Schweizer F. Antibacterial activity of amphiphilic tobramycin. The Journal of Antibiotics. 65: 495-8. PMID 22781280 DOI: 10.1038/ja.2012.59  0.48
2012 Bowler LL, Zhanel GG, Ball TB, Saward LL. Mature Pseudomonas aeruginosa biofilms prevail compared to young biofilms in the presence of ceftazidime. Antimicrobial Agents and Chemotherapy. 56: 4976-9. PMID 22777043 DOI: 10.1128/AAC.00650-12  0.48
2012 Walkty A, Baxter M, Adam H, Karlowsky JA, Lagacé-Wiens P, Hoban DJ, Zhanel GG. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011. Diagnostic Microbiology and Infectious Disease. 73: 361-4. PMID 22694789 DOI: 10.1016/j.diagmicrobio.2012.05.007  0.48
2012 Findlay B, Zhanel GG, Schweizer F. Investigating the antimicrobial peptide 'window of activity' using cationic lipopeptides with hydrocarbon and fluorinated tails. International Journal of Antimicrobial Agents. 40: 36-42. PMID 22578748 DOI: 10.1016/j.ijantimicag.2012.03.013  0.48
2012 Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Review of Anti-Infective Therapy. 10: 459-73. PMID 22512755 DOI: 10.1586/eri.12.25  0.48
2012 Lagace-Wiens PR, Duncan S, Kimani J, Thiong'o A, Shafi J, McClelland S, Sanders EJ, Zhanel G, Muraguri N, Mehta SD. Emergence of fluoroquinolone resistance in Neisseria gonorrhoeae isolates from four clinics in three regions of Kenya. Sexually Transmitted Diseases. 39: 332-4. PMID 22504591 DOI: 10.1097/OLQ.0b013e318248a85f  0.48
2012 Johnson JR, Nicolas-Chanoine MH, DebRoy C, Castanheira M, Robicsek A, Hansen G, Weissman S, Urban C, Platell J, Trott D, Zhanel G, Clabots C, Johnston BD, Kuskowski MA. Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. Emerging Infectious Diseases. 18: 598-607. PMID 22469129 DOI: 10.3201/eid1804.111627  0.48
2012 Zhanel GG, Yachison C, Nichol K, Adam H, Noreddin AM, Hoban DJ, Karlowsky JA. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model. The Journal of Antimicrobial Chemotherapy. 67: 1706-11. PMID 22467630 DOI: 10.1093/jac/dks113  0.48
2012 Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 54: S214-9. PMID 22431851 DOI: 10.1093/cid/cir920  0.48
2012 Bergeron CR, Prussing C, Boerlin P, Daignault D, Dutil L, Reid-Smith RJ, Zhanel GG, Manges AR. Chicken as reservoir for extraintestinal pathogenic Escherichia coli in humans, Canada. Emerging Infectious Diseases. 18: 415-21. PMID 22377351 DOI: 10.3201/eid1803.111099  0.48
2012 Johnson JR, Porter SB, Zhanel G, Kuskowski MA, Denamur E. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infection and Immunity. 80: 1554-62. PMID 22311928 DOI: 10.1128/IAI.06388-11  0.48
2012 Findlay B, Zhanel GG, Schweizer F. Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding. Bioorganic & Medicinal Chemistry Letters. 22: 1499-503. PMID 22285320 DOI: 10.1016/j.bmcl.2012.01.025  0.48
2012 Adam HJ, Karlowsky JA, Nichol KA, Gilmour MW, Hoban DJ, Embree J, Zhanel GG. Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine. Microbial Drug Resistance (Larchmont, N.Y.). 18: 176-82. PMID 22204595 DOI: 10.1089/mdr.2011.0197  0.48
2012 Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrobial Agents and Chemotherapy. 56: 1247-52. PMID 22203594 DOI: 10.1128/AAC.05823-11  0.48
2011 Keel RA, Zhanel GG, Zelenitsky S, Nicolau DP. Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale / Ammi Canada. 22: 132-6. PMID 23205024  0.48
2011 Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG. Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy. Drug, Healthcare and Patient Safety. 3: 59-68. PMID 22046107 DOI: 10.2147/DHPS.S15599  0.48
2011 Simner PJ, Hoban DJ, Lagacé-Wiens PR, Zhanel GG, Karlowsky JA. Fluoroquinolone resistance in Escherichia coli isolated from patients attending Canadian hospitals is associated with the ST131 clone. Diagnostic Microbiology and Infectious Disease. 71: 323-4. PMID 21889284 DOI: 10.1016/j.diagmicrobio.2011.07.016  0.48
2011 Karlowsky JA, Lagacé-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, Hoban DJ, Zhanel GG. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrobial Agents and Chemotherapy. 55: 3169-75. PMID 21537027 DOI: 10.1128/AAC.00066-11  0.48
2011 Zhanel GG, Rossnagel E, Nichol K, Cox L, Karlowsky JA, Zelenitsky S, Noreddin AM, Hoban DJ. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. The Journal of Antimicrobial Chemotherapy. 66: 1301-5. PMID 21429940 DOI: 10.1093/jac/dkr110  0.48
2011 Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrobial Agents and Chemotherapy. 55: 2837-46. PMID 21402844 DOI: 10.1128/AAC.01787-10  0.48
2011 Walkty A, Adam HJ, Laverdière M, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. Diagnostic Microbiology and Infectious Disease. 69: 348-55. PMID 21353964 DOI: 10.1016/j.diagmicrobio.2010.10.032  0.48
2011 Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. Diagnostic Microbiology and Infectious Disease. 69: 342-7. PMID 21353963 DOI: 10.1016/j.diagmicrobio.2010.10.031  0.48
2011 McCracken M, Mataseje LF, Loo V, Walkty A, Adam HJ, Hoban DJ, Zhanel GG, Mulvey MR. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study. Diagnostic Microbiology and Infectious Disease. 69: 335-41. PMID 21353962 DOI: 10.1016/j.diagmicrobio.2010.10.030  0.48
2011 Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PR, Adam HJ, Hoban DJ. Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. Diagnostic Microbiology and Infectious Disease. 69: 326-34. PMID 21353961 DOI: 10.1016/j.diagmicrobio.2010.10.029  0.48
2011 Nichol KA, Adam HJ, Hussain Z, Mulvey MR, McCracken M, Mataseje LF, Thompson K, Kost S, Lagacé-Wiens PR, Hoban DJ, Zhanel GG. Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study. Diagnostic Microbiology and Infectious Disease. 69: 320-5. PMID 21353960 DOI: 10.1016/j.diagmicrobio.2010.10.028  0.48
2011 Lagacé-Wiens PR, Simner PJ, Forward KR, Tailor F, Adam HJ, Decorby M, Karlowsky J, Hoban DJ, Zhanel GG. Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study. Diagnostic Microbiology and Infectious Disease. 69: 314-9. PMID 21353959 DOI: 10.1016/j.diagmicrobio.2010.10.027  0.48
2011 Adam HJ, DeCorby M, Rennie R, Karlowsky JA, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagnostic Microbiology and Infectious Disease. 69: 307-13. PMID 21353958 DOI: 10.1016/j.diagmicrobio.2010.10.026  0.48
2011 Zhanel GG, Adam HJ, Low DE, Blondeau J, Decorby M, Karlowsky JA, Weshnoweski B, Vashisht R, Wierzbowski A, Hoban DJ. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagnostic Microbiology and Infectious Disease. 69: 291-306. PMID 21353957 DOI: 10.1016/j.diagmicrobio.2010.10.025  0.48
2011 Hoban DJ, Zhanel GG. Introduction to the CANWARD Study (2007-2009). Diagnostic Microbiology and Infectious Disease. 69: 289-90. PMID 21353956 DOI: 10.1016/j.diagmicrobio.2010.10.024  0.48
2011 Bera S, Zhanel GG, Schweizer F. Synthesis and antibacterial activity of amphiphilic lysine-ligated neomycin B conjugates. Carbohydrate Research. 346: 560-8. PMID 21353205 DOI: 10.1016/j.carres.2011.01.015  0.48
2011 Mondal D, Zhanel GG, Schweizer F. Synthesis and antibacterial properties of carbohydrate-templated lysine surfactants. Carbohydrate Research. 346: 588-94. PMID 21316648 DOI: 10.1016/j.carres.2011.01.025  0.48
2011 Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. The Journal of Antimicrobial Chemotherapy. 66: 343-9. PMID 20926397 DOI: 10.1093/jac/dkq348  0.48
2011 Zhao N, Zhanel GG, Liu S. Regenerability of antibacterial activity of interpenetrating polymeric N-halamine and poly(ethylene terephthalate) Journal of Applied Polymer Science. 120: 611-622. DOI: 10.1002/app.33208  0.48
2011 Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG. Cumulative clinical experience from over a decade of use of levofoxacin in community-acquired pneumonia: Critical appraisal and role in therapy Drug, Healthcare and Patient Safety. 3: 59-68.  0.48
2010 Chow AW, Evans GA, Nathens AB, Ball CG, Hansen G, Harding GK, Kirkpatrick AW, Weiss K, Zhanel GG. Canadian practice guidelines for surgical intra-abdominal infections. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale / Ammi Canada. 21: 11-37. PMID 21358883  0.48
2010 Manuel J, Zhanel GG, de Kievit T. Cadaverine suppresses persistence to carboxypenicillins in Pseudomonas aeruginosa PAO1. Antimicrobial Agents and Chemotherapy. 54: 5173-9. PMID 20855735 DOI: 10.1128/AAC.01751-09  0.48
2010 Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagacé-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrobial Agents and Chemotherapy. 54: 4684-93. PMID 20805395 DOI: 10.1128/AAC.00469-10  0.48
2010 Findlay B, Zhanel GG, Schweizer F. Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold. Antimicrobial Agents and Chemotherapy. 54: 4049-58. PMID 20696877 DOI: 10.1128/AAC.00530-10  0.48
2010 Lee JC, Greenwich JL, Zhanel GG, Han X, Cumming A, Saward L, McLoughlin RM. Modulation of the local neutrophil response by a novel hyaluronic acid-binding peptide reduces bacterial burden during staphylococcal wound infection. Infection and Immunity. 78: 4176-86. PMID 20643855 DOI: 10.1128/IAI.01364-09  0.48
2010 Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 70: 859-86. PMID 20426497 DOI: 10.2165/11534440-000000000-00000  0.48
2010 Bera S, Zhanel GG, Schweizer F. Evaluation of amphiphilic aminoglycoside-peptide triazole conjugates as antibacterial agents. Bioorganic & Medicinal Chemistry Letters. 20: 3031-5. PMID 20413307 DOI: 10.1016/j.bmcl.2010.03.116  0.48
2010 Lynch JP, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Current Opinion in Pulmonary Medicine. 16: 217-25. PMID 20375783 DOI: 10.1097/MCP.0b013e3283385653  0.48
2010 Bera S, Zhanel GG, Schweizer F. Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. Journal of Medicinal Chemistry. 53: 3626-31. PMID 20373816 DOI: 10.1021/jm1000437  0.48
2010 Bera S, Zhanel GG, Schweizer F. Antibacterial activity of guanidinylated neomycin B- and kanamycin A-derived amphiphilic lipid conjugates. The Journal of Antimicrobial Chemotherapy. 65: 1224-7. PMID 20332193 DOI: 10.1093/jac/dkq083  0.48
2009 Baudry PJ, Mataseje L, Zhanel GG, Hoban DJ, Mulvey MR. Characterization of plasmids encoding CMY-2 AmpC beta-lactamases from Escherichia coli in Canadian intensive care units. Diagnostic Microbiology and Infectious Disease. 65: 379-83. PMID 19775846 DOI: 10.1016/j.diagmicrobio.2009.08.011  0.48
2009 Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrobial Agents and Chemotherapy. 53: 4915-20. PMID 19738018 DOI: 10.1128/AAC.00078-09  0.48
2009 Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008 Antimicrobial Agents and Chemotherapy. 53: 4924-4926. PMID 19704135 DOI: 10.1128/AAC.00786-09  0.48
2009 Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R. Overview of seizure-inducing potential of doripenem. Drug Safety. 32: 709-16. PMID 19670912 DOI: 10.2165/00002018-200932090-00001  0.48
2009 Zhanel GG, Baudry PJ, Tailor F, Cox L, Hoban DJ, Karlowsky JA. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. The Journal of Antimicrobial Chemotherapy. 64: 824-8. PMID 19643776 DOI: 10.1093/jac/dkp254  0.48
2009 Mccracken M, Decorby M, Fuller J, Loo V, Hoban DJ, Zhanel GG, Mulvey MR. Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: Results from CANWARD 2007 Journal of Antimicrobial Chemotherapy. 64: 552-555. PMID 19578083 DOI: 10.1093/jac/dkp225  0.48
2009 Karlowsky JA, Lagacé-Wiens PR, Low DE, Zhanel GG. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. International Journal of Antimicrobial Agents. 34: 375-9. PMID 19560902 DOI: 10.1016/j.ijantimicag.2009.05.008  0.48
2009 Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrobial Agents and Chemotherapy. 53: 3544-8. PMID 19487444 DOI: 10.1128/AAC.00400-09  0.48
2009 Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. The Journal of Antimicrobial Chemotherapy. 64: 364-9. PMID 19454524 DOI: 10.1093/jac/dkp176  0.48
2009 Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 69: 809-31. PMID 19441869 DOI: 10.2165/00003495-200969070-00003  0.48
2009 Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrobial Agents and Chemotherapy. 53: 2733-9. PMID 19398649 DOI: 10.1128/AAC.00297-09  0.48
2009 Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. International Journal of Antimicrobial Agents. 34: 82-5. PMID 19342204 DOI: 10.1016/j.ijantimicag.2009.02.002  0.48
2009 Lynch JP, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Seminars in Respiratory and Critical Care Medicine. 30: 210-38. PMID 19296420 DOI: 10.1055/s-0029-1202939  0.48
2009 Lynch JP, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Seminars in Respiratory and Critical Care Medicine. 30: 189-209. PMID 19296419 DOI: 10.1055/s-0029-1202938  0.48
2009 Serrano GN, Zhanel GG, Schweizer F. Antibacterial activity of ultrashort cationic lipo-beta-peptides. Antimicrobial Agents and Chemotherapy. 53: 2215-7. PMID 19237652 DOI: 10.1128/AAC.01100-08  0.48
2009 Baudry PJ, Nichol K, DeCorby M, Lagacé-Wiens P, Olivier E, Boyd D, Mulvey MR, Hoban DJ, Zhanel GG. Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America. Diagnostic Microbiology and Infectious Disease. 63: 319-26. PMID 19216943 DOI: 10.1016/j.diagmicrobio.2008.12.001  0.48
2009 Wierzbowski AK, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS). The Journal of Antimicrobial Chemotherapy. 63: 620-2. PMID 19151038 DOI: 10.1093/jac/dkn532  0.48
2009 Noreddin AM, El-Khatib WF, Aolie J, Salem AH, Zhanel GG. Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae. International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases. 13: 483-7. PMID 19046911 DOI: 10.1016/j.ijid.2008.08.016  0.48
2008 Lagacé-Wiens PR, Decorby MR, Baudry PJ, Hoban DJ, Karlowsky JA, Zhanel GG. Differences in antimicrobial susceptibility in Escherichia coli from Canadian intensive care units based on regional and demographic variables. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale / Ammi Canada. 19: 282-6. PMID 19436508  0.48
2008 Zhanel GG, Decorby M, Nichol KA, Baudry PJ, Karlowsky JA, Lagace-Wiens PR, McCracken M, Mulvey MR, Hoban DJ. Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006). The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale / Ammi Canada. 19: 243-9. PMID 19412382  0.48
2008 Bera S, Zhanel GG, Schweizer F. Design, synthesis, and antibacterial activities of neomycin-lipid conjugates: polycationic lipids with potent gram-positive activity. Journal of Medicinal Chemistry. 51: 6160-4. PMID 18778047 DOI: 10.1021/jm800345u  0.48
2008 Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile Antimicrobial Agents and Chemotherapy. 52: 4163-4165. PMID 18725442 DOI: 10.1128/AAC.00476-08  0.48
2008 Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. American Journal of Clinical Dermatology. 9: 245-54. PMID 18572975 DOI: 10.2165/00128071-200809040-00004  0.48
2008 Zhang K, Mondal D, Zhanel GG, Schweizer F. Synthesis of glucose-templated lysine analogs and incorporation into the antimicrobial dipeptide sequence kW-OBn. Carbohydrate Research. 343: 1644-52. PMID 18452902 DOI: 10.1016/j.carres.2008.04.018  0.48
2008 Gawande PV, Lovetri K, Yakandawala N, Romeo T, Zhanel GG, Cvitkovitch DG, Madhyastha S. Antibiofilm activity of sodium bicarbonate, sodium metaperiodate and SDS combination against dental unit waterline-associated bacteria and yeast Journal of Applied Microbiology. 105: 986-992. PMID 18422552 DOI: 10.1111/j.1365-2672.2008.03823.x  0.48
2008 Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study Journal of Antimicrobial Chemotherapy. 62: 206-208. PMID 18385143 DOI: 10.1093/jac/dkn140  0.48
2008 Zhanel GG, Baudry P, Vashisht V, Laing N, Noreddin AM, Hoban DJ. Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum β-lactamase-producing Escherichia coli using an in vitro model Journal of Antimicrobial Chemotherapy. 61: 643-646. PMID 18238885 DOI: 10.1093/jac/dkm533  0.48
2008 Nichol KA, Adam HJ, Karlowsky JA, Zhanel GG, Hoban DJ. Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005 Antimicrobial Agents and Chemotherapy. 52: 1190-1194. PMID 18180349 DOI: 10.1128/AAC.01260-07  0.48
2007 Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: A Monte Carlo simulation analysis Clinical Therapeutics. 29: 2685-2689. PMID 18201584 DOI: 10.1016/j.clinthera.2007.12.019  0.48
2007 Wierzbowski AK, Nichol K, Laing N, Hisanaga T, Nikulin A, Karlowsky JA, Hoban DJ, Zhanel GG. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004). The Journal of Antimicrobial Chemotherapy. 60: 733-40. PMID 17673477 DOI: 10.1093/jac/dkm273  0.48
2007 Karlowsky JA, Kasloff S, Nichol KA, Hoban DJ, Zhanel GG. Genetic relatedness of multidrug-resistant Escherichia coli cultured from geographically diverse outpatient, midstream urine specimens Diagnostic Microbiology and Infectious Disease. 58: 283-287. PMID 17376632 DOI: 10.1016/j.diagmicrobio.2007.01.012  0.48
2007 Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ, Zhanel GG. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial Agents and Chemotherapy. 51: 1580-1. PMID 17220418 DOI: 10.1128/AAC.01254-06  0.48
2007 Bradley JS, Guidos R, Baragona S, Bartlett JG, Rubinstein E, Zhanel GG, Tino MD, Pompliano DL, Tally F, Tipirneni P, Tillotson GS, Powers JH, Tillotson GS. Anti-infective research and development--problems, challenges, and solutions. The Lancet. Infectious Diseases. 7: 68-78. PMID 17182346 DOI: 10.1016/S1473-3099(06)70689-2  0.48
2007 Zhanel GG, Derkatch S, Laing N, Noreddin AM, Hoban DJ. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model Journal of Antimicrobial Chemotherapy. 59: 144-147. PMID 17079238 DOI: 10.1093/jac/dkl433  0.48
2007 Zhanel GG, Low DE. Launching of the CAN-R Web site - The official Web site of the Canadian Antimicrobial Resistance Alliance Canadian Journal of Infectious Diseases and Medical Microbiology. 18: 151-152.  0.48
2006 Hoban DJ, Zhanel GG. Clinical implications of macrolide resistance in community-acquired respiratory tract infections Expert Review of Anti-Infective Therapy. 4: 973-980. PMID 17181414 DOI: 10.1586/14787210.4.6.973  0.48
2006 Lynch JP, File TM, Zhanel GG. Levofloxacin for the treatment of community-acquired pneumonia Expert Review of Anti-Infective Therapy. 4: 725-742. PMID 17140350 DOI: 10.1586/14737140.4.5.725  0.48
2006 Zhanel GG, Wang X, Nichol K, Nikulin A, Wierzbowski AK, Mulvey M, Hoban DJ. Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004. International Journal of Antimicrobial Agents. 28: 465-71. PMID 17049211 DOI: 10.1016/j.ijantimicag.2006.08.005  0.48
2006 Schurek KN, Adam HJ, Hoban DJ, Zhanel GG. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae International Journal of Antimicrobial Agents. 28: 266-269. PMID 16904294 DOI: 10.1016/j.ijantimicag.2006.04.007  0.48
2006 Karlowsky JA, Hoban DJ, DeCorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study Antimicrobial Agents and Chemotherapy. 50: 2251-2254. PMID 16723598 DOI: 10.1128/AAC.00123-06  0.48
2006 Zhanel GG, Mayer M, Laing N, Adam HJ. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy. 50: 2228-2230. PMID 16723591 DOI: 10.1128/AAC.01620-05  0.48
2006 Zhanel GG, James J, Derkatch S, Laing N, Noreddin AM, Hoban DJ. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae Journal of Antimicrobial Chemotherapy. 58: 112-116. PMID 16644764 DOI: 10.1093/jac/dkl159  0.48
2006 Wierzbowski AK, Hoban DJ, Hisanaga T, DeCorby M, Zhanel GG. The use of macrolides in treatment of upper respiratory tract infections. Current Allergy and Asthma Reports. 6: 171-81. PMID 16566868 DOI: 10.1007/s11882-006-0056-x  0.48
2006 ZhaneL GG, Karlowsky JA, Rubinstein E, Hoban D. Tigecycline: A novel glycylcycline antibiotic Expert Review of Anti-Infective Therapy. 4: 9-25. PMID 16441206 DOI: 10.1586/14787210.4.1.9  0.48
2006 Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species International Journal of Antimicrobial Agents. 27: 174-177. PMID 16414247 DOI: 10.1016/j.ijantimicag.2005.10.014  0.48
2006 Nicolle LE, Zhanel GG, Harding GKM. Microbiological outcomes in women with diabetes and untreated asymptomatic bacteriuria World Journal of Urology. 24: 61-65. PMID 16389540 DOI: 10.1007/s00345-005-0042-2  0.48
2006 Zhanel GG, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin AM, Gin AS, Rubinstein E, Hoban DJ. A review of new fluoroquinolones: Focus on their use in respiratory tract infections Treatments in Respiratory Medicine. 5: 437-465. DOI: 10.2165/00151829-200605060-00009  0.48
2006 Zhanel GG, Hisanaga T, Wierzbowski A, Hoban DJ. Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia Therapeutics and Clinical Risk Management. 2: 59-75.  0.48
2005 Lynch JP, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: Implications for therapy Seminars in Respiratory and Critical Care Medicine. 26: 575-616. PMID 16388429 DOI: 10.1055/s-2005-925524  0.48
2005 Wierzbowski AK, Boyd D, Mulvey M, Hoban DJ, Zhanel GG. Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides. Antimicrobial Agents and Chemotherapy. 49: 4635-40. PMID 16251306 DOI: 10.1128/AAC.49.11.4635-4640.2005  0.48
2005 Khaliq Y, Zhanel GG. Musculoskeletal injury associated with fluoroquinolone antibiotics Clinics in Plastic Surgery. 32: 495-502. PMID 16139623 DOI: 10.1016/j.cps.2005.05.004  0.48
2005 Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: Pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae International Journal of Antimicrobial Agents. 26: 120-125. PMID 16046101 DOI: 10.1016/j.ijantimicag.2005.04.012  0.48
2005 Hisanaga T, Hoban DJ, Zhanel GG. Mechanisms of resistance to telithromycin in Streptococcus pneumoniae Journal of Antimicrobial Chemotherapy. 56: 447-450. PMID 16006449 DOI: 10.1093/jac/dki249  0.48
2005 Zhanel GG, Johanson C, Laing N, Hisanaga T, Wierzbowski A, Hoban DJ. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary Antimicrobial Agents and Chemotherapy. 49: 1943-1948. PMID 15855517 DOI: 10.1128/AAC.49.5.1943-1948.2005  0.48
2005 Wierzbowski AK, Hoban DJ, Hisanaga T, Decorby M, Zhanel GG. The Use of Macrolides in Treatment of Upper Respiratory Tract Infections. Current Infectious Disease Reports. 7: 175-184. PMID 15847719  0.48
2005 Zhanel GG. Antibacterial drivers of resistance Treatments in Respiratory Medicine. 4: 13-18. PMID 15846152  0.48
2005 Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, Hoban DJ. Ertapenem: Review of a new carbapenem Expert Review of Anti-Infective Therapy. 3: 23-39. PMID 15757455 DOI: 10.1586/14787210.3.1.23  0.48
2005 Wierzbowski AK, Swedlo D, Boyd D, Mulvey M, Nichol KA, Hoban DJ, Zhanel GG. Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002. Antimicrobial Agents and Chemotherapy. 49: 1257-61. PMID 15728944 DOI: 10.1128/AAC.49.3.1257-1261.2005  0.48
2005 Smith-Adam HJ, Nichol KA, Hoban DJ, Zhanel GG. Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants Antimicrobial Agents and Chemotherapy. 49: 846-848. PMID 15673786 DOI: 10.1128/AAC.49.2.846-848.2005  0.48
2005 Noreddin AM, Haynes VL, Zhanel GG. Pharmacokinetics and pharmacodynamics of the new quinolones Journal of Pharmacy Practice. 18: 432-443. DOI: 10.1177/0897190005282397  0.48
2004 Zhanel GG, Hoban DJ, Schurek K, Karlowsky JA. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa International Journal of Antimicrobial Agents. 24: 529-535. PMID 15555873 DOI: 10.1016/j.ijantimicag.2004.08.003  0.48
2004 Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). International Journal of Antimicrobial Agents. 24: 479-84. PMID 15519481 DOI: 10.1016/j.ijantimicag.2004.06.010  0.48
2004 Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates Antimicrobial Agents and Chemotherapy. 48: 3954-3958. PMID 15388458 DOI: 10.1128/AAC.48.10.3954-3958.2004  0.48
2004 Carrie AG, Metge CJ, Collins DM, Harding GK, Zhanel GG. Predictors of receipt of a fluoroquinolone versus trimethoprim-sulfamethoxazole for treatment of acute pyelonephritis in women in Manitoba, Canada. Pharmacoepidemiology and Drug Safety. 13: 863-70. PMID 15386718 DOI: 10.1002/pds.949  0.48
2004 Rzeszutek M, Wierzbowski A, Hoban DJ, Conly J, Bishai W, Zhanel GG. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae International Journal of Antimicrobial Agents. 24: 95-104. PMID 15288306 DOI: 10.1016/j.ijantimicag.2004.03.008  0.48
2004 Zhanel GG, Wierzbowski AK, Hisanaga P, Hoban DJ. The Use of Ketolides in Treatment of Upper Respiratory Tract Infections. Current Infectious Disease Reports. 6: 191-199. PMID 15142482  0.48
2004 Carrie AG, Metge CJ, Collins DM, Harding GK, Zhanel GG. Use of administrative healthcare claims to examine the effectiveness of trimethoprim-sulfamethoxazole versus fluoroquinolones in the treatment of community-acquired acute pyelonephritis in women. The Journal of Antimicrobial Chemotherapy. 53: 512-7. PMID 14749344 DOI: 10.1093/jac/dkh100  0.48
2004 Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 64: 63-88. PMID 14723559 DOI: 10.2165/00003495-200464010-00005  0.48
2004 Zhanel GG, Embil J. Tendiopathy and fluoroquinolones: What is the risk? Journal of Respiratory Diseases. 25: 227.  0.48
2004 Zhanel GG, Rubinstein E, Naber KG, Mazzulli T. Ciprofloxacin Extended Release Drugs and Aging. 21: 65-66.  0.48
2004 Makowsky MJ, Smith KK, Ariano RE, Zhanel GG, Gin AS. An assessment of vancomycin use in 2 tertiary care hospitals Canadian Journal of Hospital Pharmacy. 57: 150-157.  0.48
2003 Zhanel GG, Hisanaga T, Nichol K, Wierzbowski A, Hoban DJ. Ketolides: An emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae Expert Opinion On Emerging Drugs. 8: 297-321. PMID 14661991 DOI: 10.1517/14728214.8.2.297  0.48
2003 Livermore DM, Smith HJ, Hoban DJ, Zhanel GG. Overstretching the mutant prevention concentration (multiple letters) [2] Journal of Antimicrobial Chemotherapy. 52: 732-733. PMID 12972447 DOI: 10.1093/jac/dkg377  0.48
2003 Zhanel GG, Noreddin AM. Fluoroquinolone AUIC break points and the link to bacterial killing rates: In vitro models Annals of Pharmacotherapy. 37: 1331-1334. PMID 12921519 DOI: 10.1345/aph.1D095  0.48
2003 Zhanel GG, DeCorby M, Noreddin A, Mendoza C, Cumming A, Nichol K, Wierzbowski A, Hoban DJ. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. The Journal of Antimicrobial Chemotherapy. 52: 83-8. PMID 12775677 DOI: 10.1093/jac/dkg278  0.48
2003 Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: A critical review of the literature Clinical Infectious Diseases. 36: 1404-1410. PMID 12766835 DOI: 10.1086/375078  0.48
2003 Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 Antimicrobial Agents and Chemotherapy. 47: 1875-1881. PMID 12760861 DOI: 10.1128/AAC.47.6.1875-1881.2003  0.48
2003 Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 Antimicrobial Agents and Chemotherapy. 47: 1867-1874. PMID 12760860 DOI: 10.1128/AAC.47.6.1867-1874.2003  0.48
2003 Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Saunders KA, Miller LA, Poupard JA, Baron EJ, Sherretta A, Thomson R, Low D, Hoban D, Church D, Kibsey P, et al. Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study International Journal of Antimicrobial Agents. 21: 425-433. PMID 12727075 DOI: 10.1016/S0924-8579(03)00038-4  0.48
2003 Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Stretching the mutant prevention concentration (MPC) beyond its limits Journal of Antimicrobial Chemotherapy. 51: 1323-1325. PMID 12716780 DOI: 10.1093/jac/dkg255  0.48
2003 Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Saunders KA, Miller LA, Poupard JA. Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21,232 clinical isolates from Europe European Journal of Clinical Microbiology and Infectious Diseases. 22: 261-267. PMID 12709842 DOI: 10.1007/s10096-002-0876-0  0.48
2003 Zhanel GG, Walkty A, Nichol K, Smith H, Noreddin A, Hoban DJ. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada Diagnostic Microbiology and Infectious Disease. 45: 63-67. PMID 12573552 DOI: 10.1016/S0732-8893(02)00498-4  0.48
2003 Nichol KA, Zhanel GG, Hoban DJ. Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada Antimicrobial Agents and Chemotherapy. 47: 804-808. PMID 12543698 DOI: 10.1128/AAC.47.2.804-808.2003  0.48
2003 Zhanel GG. In vitro activity of garenoxacin, a novel des-F(6)-fluoroquinolone Clinical Microbiology Newsletter. 25: 153-159. DOI: 10.1016/S0196-4399(03)80049-1  0.48
2002 Noreddin AM, Roberts D, Nichol K, Wierzbowski A, Hoban DJ, Zhanel GG. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations Antimicrobial Agents and Chemotherapy. 46: 4029-4034. PMID 12435719 DOI: 10.1128/AAC.46.12.4029-4034.2002  0.48
2002 Harding GKM, Zhanel GG, Nicolle LE, Cheang M. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria New England Journal of Medicine. 347: 1576-1583. PMID 12432044 DOI: 10.1056/NEJMoa021042  0.48
2002 Nichol KA, Zhanel GG, Hoban DJ. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae Antimicrobial Agents and Chemotherapy. 46: 3261-3264. PMID 12234855 DOI: 10.1128/AAC.46.10.3261-3264.2002  0.48
2002 Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ. The ketolides: a critical review. Drugs. 62: 1771-804. PMID 12149046 DOI: 10.2165/00003495-200262120-00006  0.48
2002 Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: The facts behind the claims Journal of Antimicrobial Chemotherapy. 49: 893-895. PMID 12039880  0.48
2002 Low DE, De Azavedo J, Weiss K, Mazzulli T, Kuhn M, Church D, Forward K, Zhanel G, Simor A, Krajden S, Price R, Paradis JF, Bocci L, Savard M, Rudrick BF, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000 Antimicrobial Agents and Chemotherapy. 46: 1295-1301. PMID 11959559 DOI: 10.1128/AAC.46.5.1295-1301.2002  0.48
2002 Embil JM, Zhanel GG, Plourde PJ, Hoban D. Scissors: A potential source of nosocomial infection Infection Control and Hospital Epidemiology. 23: 147-151. PMID 11918121  0.48
2002 Zhanel GG, Hoban DJ. Ketolides in the treatment of respiratory infections Expert Opinion On Pharmacotherapy. 3: 277-297. PMID 11866679 DOI: 10.1517/14656566.3.3.277  0.48
2001 Mazzulli T, Skulnick M, Small G, Marshall W, Hoban DJ, Zhanel GG, Finn S, Low DE. Susceptibility of community Gram-negative urinary tract isolates to mecillinam and other oral agents. The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses. 12: 289-92. PMID 18159352 DOI: 10.1155/2001/601743  0.48
2001 Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: Focus on respiratory infections Current Opinion in Pharmacology. 1: 459-463. PMID 11764770 DOI: 10.1016/S1471-4892(01)00080-7  0.48
2001 Hoban DJ, Wierzbowski AK, Nichol K, Zhanel GG. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrobial Agents and Chemotherapy. 45: 2147-50. PMID 11408241 DOI: 10.1128/AAC.45.7.2147-2150.2001  0.48
2001 Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA. Influence of human serum on antifungal pharmacodynamics with Candida albicans Antimicrobial Agents and Chemotherapy. 45: 2018-2022. PMID 11408217 DOI: 10.1128/AAC.45.7.2018-2022.2001  0.48
2001 Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, Karlowsky JA. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 61: 443-98. PMID 11324679 DOI: 10.2165/00003495-200161040-00003  0.48
2001 Zhanel GG, Walters M, Laing N, Hoban DJ. In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae Journal of Antimicrobial Chemotherapy. 47: 435-440. PMID 11266416  0.48
2001 Zhanel GG, Hoban DJ, Karlowsky JA. Nitrofurantoin is active against vancomycin-resistant enterococci Antimicrobial Agents and Chemotherapy. 45: 324-326. PMID 11120989 DOI: 10.1128/AAC.45.1.324-326.2001  0.48
2001 Klepser ME, Lewis RE, Ernst EJ, Rosemarie Petzold C, Bailey EM, Burgess DS, Carver PL, Lacy MK, Mercier RC, Nicolau DP, Zhanel GG, Pfaller MA. Multi-center evaluation of antifungal time-kill methods Journal of Infectious Disease Pharmacotherapy. 5: 29-41. DOI: 10.1300/J100v05n02_04  0.48
2001 Zhanel GG, Schroeder C, Vercaigne L, Gin AS, Embil J, Hoban DJ. A critical review of oxazolidinones: An alternative or replacement for glycopeptides and streptogramins? Canadian Journal of Infectious Diseases. 12: 379-390.  0.48
2000 Karlowsky JA, Verma G, Zhanel GG, Hoban DJ. Presence of ROB-1 β-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae Journal of Antimicrobial Chemotherapy. 45: 871-875. PMID 10837442  0.48
2000 Zhanel GG, Karlowsky JA, Low DE, Hoban DJ. Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998 Journal of Antimicrobial Chemotherapy. 45: 655-662. PMID 10797089  0.48
2000 Carrie AG, Metge CJ, Zhanel GG. Antibiotic use in a Canadian province, 1995-1998 Annals of Pharmacotherapy. 34: 459-464. PMID 10772430  0.48
2000 Vercaigne LM, Zhanel GG. Antibiotic-heparin lock: In vitro confirmation of antibacterial activity Canadian Journal of Hospital Pharmacy. 53: 193-198.  0.48
1999 Hoban DJ, Zhanel GG, Karlowsky JA. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Diagnostic Microbiology and Infectious Disease. 35: 37-44. PMID 10529880 DOI: 10.1016/S0732-8893(99)00053-X  0.48
1999 Karlowsky JA, Zhanel GG, Hoban DJ. Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals Diagnostic Microbiology and Infectious Disease. 35: 1-7. PMID 10529874 DOI: 10.1016/S0732-8893(99)00045-0  0.48
1999 Zhanel GG, Karlowsky JA, Palatnick L, Vercaigne L, Low DE, Hoban DJ. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a canadian national surveillance study Antimicrobial Agents and Chemotherapy. 43: 2504-2509. PMID 10508032  0.48
1999 Carrie AG, Zhanel GG. Antibacterial use in community practice. Assessing quantity, indications and appropriateness, and relationship to the development of antibacterial resistance Drugs. 57: 871-881. PMID 10400402 DOI: 10.2165/00003495-199957060-00004  0.48
1999 Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients Antimicrobial Agents and Chemotherapy. 43: 1463-1464. PMID 10348771  0.48
1999 Zelenitsky SA, Booker B, Laing N, Karlowsky JA, Hoban DJ, Zhanel GG. Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple- dose, in vitro pharmacodynamic model Antimicrobial Agents and Chemotherapy. 43: 592-597. PMID 10049272  0.48
1999 Balko T, Karlowsky JA, Palatnick LP, Zhanel GG, Hoban DJ. Characterization of the inoculum effect with Haemophilus influenzae and β-lactams Diagnostic Microbiology and Infectious Disease. 33: 47-58. PMID 9990476 DOI: 10.1016/S0732-8893(98)00117-5  0.48
1999 Karlowsky JA, Gin AS, Cooper R, Hoban DJ, Zhanel GG. Use of intravenous ciprofloxacin in a Canadian medical centre Drugs. 58: 271-272. DOI: 10.2165/00003495-199958002-00088  0.48
1999 Zhanel GG, Walkty A, Vercaigne L. Trovafloxacin/alatrofloxacin associated hepatotoxicity Canadian Journal of Infectious Diseases. 10: 273.  0.48
1999 Zhanel GG, Siemens S, Slayter K, Mandell L. Antibiotic and oral contraceptive drug interactions: Is there a need for concern? Canadian Journal of Infectious Diseases. 10: 429-433.  0.48
1998 Vercaigne LM, Zhanel GG. Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on warfarins Journal of Pharmacy &Amp; Pharmaceutical Sciences : a Publication of the Canadian Society For Pharmaceutical Sciences, SociéTé Canadienne Des Sciences Pharmaceutiques. 1: 92-94. PMID 10948395  0.48
1998 Zhanel GG, Karlowsky JA, Schwartz B, Jensen SB, Hoban DJ. Mecillinam activity compared to ampicillin, trimethoprim/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli Chemotherapy. 44: 391-396. PMID 9755298 DOI: 10.1159/000007149  0.48
1998 Zhanel GG, Karlowsky JA, Zelenitsky SA, Turik MA, Hoban DJ. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents Antimicrobial Agents and Chemotherapy. 42: 2446-2448. PMID 9736582  0.48
1998 Zhanel GG, Kirkpatrick IDC, Hoban DJ, Kabani AM, Karlowsky JA. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus Antimicrobial Agents and Chemotherapy. 42: 2427-2430. PMID 9736576  0.48
1998 Turenne CY, Hoban DJ, Karlowsky JA, Zhanel GG, Kabani AM. Screening of stool samples for identification of vancomycin-resistant Enterococcus isolates should include the methyl-α-D-glucopyranoside test to differentiate nonmotile Enterococcus gallinarum from E. faecium Journal of Clinical Microbiology. 36: 2333-2335. PMID 9666016  0.48
1998 Zhanel GG, Karlowsky JA, Hoban DJ. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species Diagnostic Microbiology and Infectious Disease. 31: 343-347. PMID 9635908 DOI: 10.1016/S0732-8893(98)00019-4  0.48
1998 Zelenitsky SA, Karlowsky JA, Hoban DJ, Kabani A, Zhanel GG. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model Chemotherapy. 44: 1-6. PMID 9444401 DOI: 10.1159/000007083  0.48
1998 Lawson CA, Karlowsky JA, Zhanel GG. Fluconazole-induced hepatotoxicity: Review of published case reports Canadian Journal of Hospital Pharmacy. 51: 61-63.  0.48
1998 Zhanel GG, Simor AE, Vercaigne L, Mandell L. Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects Canadian Journal of Infectious Diseases. 9: 215-228.  0.48
1998 Osson C, Cunningham S, Zhanel GG, Simor AE, Vercaigne L, Mandell L. Addition information concerning the comparison of imipenem and meropenem [1] (multiple letters) Canadian Journal of Infectious Diseases. 9: 322-326.  0.48
1997 Karlowsky JA, Zhanel GG, Klym KA, Hoban DJ, Kabani AM. Candidemia in a Canadian tertiary care hospital from 1976 to 1996 Diagnostic Microbiology and Infectious Disease. 29: 5-9. PMID 9350409 DOI: 10.1016/S0732-8893(97)00068-0  0.48
1997 Karlowsky JA, Hoban DJ, Zelenitsky SA, Zhanel GG. Altered denA and anr gene expression in aminoglycoside adaptive resistance in Pseudomonas aeruginosa Journal of Antimicrobial Chemotherapy. 40: 371-376. PMID 9338489 DOI: 10.1093/jac/40.3.371  0.48
1997 Zelenitsky SA, Karlowsky JA, Zhanel GG, Hoban DJ, Nicas T. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains [2] Antimicrobial Agents and Chemotherapy. 41: 1407-1408. PMID 9174212  0.48
1997 Karlowsky JA, Zelenitsky SA, Zhanel GG. Aminoglycoside adaptive resistance Pharmacotherapy. 17: 549-555. PMID 9165557  0.48
1997 Armas M, Sahai J, Zhanel GG. Current status of the HIV vaccine Canadian Journal of Hospital Pharmacy. 50: 5-8.  0.48
1996 Rapp RP, Gin AS, Zhanel GG. Comment: Vancomycin-resistant enterococci [8] Annals of Pharmacotherapy. 30: 1500. PMID 9063961  0.48
1996 Zelenitsky SA, Zhanel GG. Phenazopyridine in urinary tract infections Annals of Pharmacotherapy. 30: 866-868. PMID 8826573  0.48
1996 Gin AS, Zhanel GG. Vancomycin-resistant enterococci Annals of Pharmacotherapy. 30: 615-624. PMID 8792949  0.48
1996 Drobot GR, Karlowsky JA, Hoban DJ, Zhanel GG. Antibiotic activity in microbiological media versus that in human urine: Comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazolc Antimicrobial Agents and Chemotherapy. 40: 237-240. PMID 8787914  0.48
1996 Karlowsky JA, Saunders MH, Harding GAJ, Hoban DJ, Zhanel GG. In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy. 40: 1387-1393. PMID 8726006  0.48
1996 Majcherczyk PA, Zhanel GG. The issue of the true postantibiotic effect [2] Journal of Antimicrobial Chemotherapy. 37: 188-190. PMID 8647763 DOI: 10.1093/jac/37.1.188  0.48
1995 Zhanel GG, Nicolle LE, Harding GKM, Cowden E, Kaufman B, Ludwig S, Matwijiw I, Mehta A, Moorhouse J, Murphy L, Rowe R, Salamon B, Woo V, Thomson M, Rubin M, et al. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus Clinical Infectious Diseases. 21: 316-322. PMID 8562738 DOI: 10.1093/clinids/21.2.316  0.48
1995 Kroeker JS, Karlowsky JA, Zhanel GG. Recommendations for the calculation of the post-antibiotic effect for β-lactams and gram-negative bacilli Journal of Antimicrobial Chemotherapy. 35: 551-552. PMID 7628990 DOI: 10.1093/jac/35.4.551  0.48
1994 Vercaigne LM, Zhanel GG. Recommended treatment for urinary tract infection in pregnancy Annals of Pharmacotherapy. 28: 248-251. PMID 8173146 DOI: 10.1177/106002809402800218  0.48
1994 Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Postantibiotic effect in pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro Journal of Antimicrobial Chemotherapy. 33: 937-947. PMID 8089067 DOI: 10.1093/jac/33.5.937  0.48
1994 Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy. 38: 1165-1168. PMID 8067757  0.48
1994 Zhanel GG, Craig WA. Pharmacokinetic Contributions to Postantibiotic Effects: Focus on Aminoglycosides Clinical Pharmacokinetics. 27: 377-392. PMID 7851055 DOI: 10.2165/00003088-199427050-00005  0.48
1993 Karlowsky JA, Zhanel GG, Davidson RJ, Zieroth SR, Hoban DJ. In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth Antimicrobial Agents and Chemotherapy. 37: 1154-1157. PMID 8517705  0.48
1993 Zhanel GG, Kim SO, Davidson RJ, Hoban DJ, Nicolle LE. Effect of subinhibitory concentrations of ciprofloxacin and gentamicin on the adherence of Pseudomonas aeruginosa to vero cells and voided uroepithelial cells Chemotherapy. 39: 105-111. PMID 8458242 DOI: 10.1159/000239110  0.48
1993 Zhanel GG. Changing strategies in aminoglycoside dosing; the result of research on antimicrobial pharmacodynamics Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology. 279: 447-449. PMID 8305801  0.48
1992 Zhanel GG, Pharm D, Ariano RE. Once daily aminoglycoside dosing: Maintained efficacy with reduced nephrotoxicity? Renal Failure. 14: 1-9. PMID 1561384 DOI: 10.3109/08860229209039110  0.48
1992 Zhanel GG, Karlowsky JA, Davidson RJ, Hoban DJ. Effect of pooled human cerebrospinal fluid on the postantibiotic effects of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli Antimicrobial Agents and Chemotherapy. 36: 1136-1139. PMID 1510407  0.48
1992 Zhanel GG, Nicolle LE. Effect of subinhibitory antimicrobial concentrations (sub-MICs) on in-vitro bacterial adherence to uroepithelial cells Journal of Antimicrobial Chemotherapy. 29: 617-627. PMID 1506346 DOI: 10.1093/jac/29.6.617  0.48
1992 Karlowsky JA, Zhanel GG. Concepts on the use of liposomal antimicrobial agents: Applications for aminoglycosides Clinical Infectious Diseases. 15: 654-667. PMID 1420679 DOI: 10.1093/clind/15.4.654  0.48
1992 Zhanel GG, Crampton J, Kim S, Nicolle LE, Davidson RJ, Hoban DJ. Antimicrobial activity of subinhibitory concentrations of ciprofloxacin against Pseudomonas aeruginosa as determined by the killing curve method and the postantibiotic effect Chemotherapy. 38: 388-394. PMID 1288962 DOI: 10.1159/000239032  0.48
1991 Ariano RE, Zhanel GG. Antimicrobial prophylaxis in coronary bypass surgery: A critical appraisal Dicp, Annals of Pharmacotherapy. 25: 478-484. PMID 2068834  0.48
1991 Zhanel GG, Hoban DJ, Harding GKm. The postantibiotic effect: A review of in vitro and in vivo data Annals of Pharmacotherapy. 25: 153-163. PMID 2058187 DOI: 10.1177/106002809102500210  0.48
1991 Davidson RJ, Zhanel GG, Phillips R, Hoban DJ. Human serum enhances the postantibiotic effect of fluoroquinolones against Staphylococcus aureus Antimicrobial Agents and Chemotherapy. 35: 1261-1263. PMID 1929278  0.48
1991 Zhanel GG, Karlowsky JA, Hoban DJ, Davidson RJ. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect Chemotherapy. 37: 114-121. PMID 1903340 DOI: 10.1159/000238842  0.48
1991 Zhanel GG, Karlowsky JA, Davidson RJ, Hoban DJ. Influence of human urine on the in vitro activity and postantibiotic effect of ciprofloxacin against Escherichia coli Chemotherapy. 37: 218-223. PMID 1889309  0.48
1990 Zhanel GG, Harding GKM, Guay DRP. Asymptomatic bacteriuria: Which patients should be treated? Archives of Internal Medicine. 150: 1389-1396. PMID 2196024  0.48
1990 Ariano RE, Zhanel GG, Harding GKM. The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis Cmaj. 142: 1049-1051. PMID 2186849  0.48
1990 Zhanel GG. Cephalosporin-induced nephrotoxicity: Does it exist? Dicp, Annals of Pharmacotherapy. 24: 262-265. PMID 2180220  0.48
1990 Zhanel GG, Davidson RJ, Hoban DJ. Reproducibility of the in-vitro postantibiotic effect of fluoroquinolones against staphylococcus aureus Journal of Antimicrobial Chemotherapy. 26: 724-726. PMID 2079455 DOI: 10.1093/jac/26.5.724  0.48
1990 Zhanel GG, Harding GKM, Nicolle LE. Asymptomatic bacteriuria in patients with diabetes mellitus Reviews of Infectious Diseases. 13: 150-154. PMID 2017615 DOI: 10.1093/clinids/12.5.150  0.48
1990 Zhanel GG, Gin AS, Przybylo A, Louie TJ, Otten NH. Effect of interventions on prescribing of antimicrobials for prophylaxis in obstetric and gynecologic surgery Obstetrical and Gynecological Survey. 45: 753-754.  0.48
1989 Conway B, Zhanel GG, Ronald AR. The value of single-dose therapy to diagnose the site of urinary infection International Journal of Experimental and Clinical Chemotherapy. 2: 39-46. DOI: 10.1159/000238807  0.48
1989 Richard A, Zhanel GG. Treatment of vaginal pinworms Canadian Journal of Hospital Pharmacy. 42: 208-209.  0.48
1988 Zhanel GG, Ronald AR. Single-dose versus traditional therapy for uncomplicated urinary tract infections Drug Intelligence and Clinical Pharmacy. 22: 21-24. PMID 3280278  0.48
1988 Zhanel GG. AIDS - acquired immunodeficiency syndrome - a review Canadian Journal of Hospital Pharmacy. 41: 49-54+61.  0.48
1988 Zhanel GG, Brunham RC. Third-generation cephalosporins Canadian Journal of Hospital Pharmacy. 41: 183-194.  0.48
1986 Matzke GR, Zhanel GG, Guay DRP. Clinical Pharmacokinetics of Vancomycin Clinical Pharmacokinetics. 11: 257-282. PMID 3530582 DOI: 10.2165/00003088-198611040-00001  0.48
1986 Zhanel GG, Bleske BE. Converting Patients From Intravenous Lidocaine to Oral Tocainide Treatment Jama: the Journal of the American Medical Association. 255: 3361-3362. PMID 3086579 DOI: 10.1001/jama.1986.03370240031015  0.48
Show low-probability matches.